Trovagene, a developer of transrenal molecular diagnostics, has named Charlie Rodi, Ph.D., vice president and chief technology officer.

Rodi has held varying positions at GD Searle, Monsanto Genome Sequencing Center, Sequenom and ICx BioSystems, several as vice president or director. He was among the first to use nucleic acid biomarkers in the development of pharmaceuticals, and more recently he established the use of digital PCR in detection of rare alleles in circulating nucleic acids and transcript profiling in circulating tumor cells.

In addition to his expertise and innovation in the detection of nucleic acids, Rodi has been awarded several NIH grants in the area of infectious diseases.

Rodi has been working with the Trovagene leadership team as a consultant since December 2011, and has already contributed greatly to the company’s strategy of mutation detection in the management of cancer and in optimizing the company’s program in HPV detection.